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Background/aim: We examined the protective effects of the natural flavonoid, quercetin, against cerebral vasospasm in an experimental
rat subarachnoid haemorrhage (SAH) model.
Materials and methods: Thirty-eight albino Wistar rats were divided into five groups as follows: group 1 (G1, n=8), no experimental
intervention; group 2 (G2, n=8), subarachnoid physiological saline; group 3 (G3, n=8), SAH; group 4 (G4, n=7) SAH and low-dose (10
mg/kg) quercetin treatment; group 5 (G5, n=7), SAH and high-dose (50 mg/kg) quercetin treatment. Subarachnoid haemorrhage was
induced by injection of 0.15 cc of autologous blood taken from the tail artery into the cisterna magna from the craniocervical junction
and basilar arteries and blood samples were taken for biochemical and histopathological analyses.
Results: Malondialdehyde (MDA) levels were significantly higher in G2 and G3 than in G1 (P < 0.05). Significant decreases in MDA
were observed in G4 and G5 compared with G2 (P < 0.05, G4–G2; P < 0.05, G5–G2). There were no significant differences between G2
and G3 or among G1, G4, and G5. No statistically significant differences were found in total antioxidant capacity between the groups (P
> 0.05). There were no significant differences in basilar artery (BA) wall thickness between G3 and G4 or between G3 and G5, but G4
and G5 showed greater luminal diameters than G3 (P < 0.05). There were no significant differences in BA thickness or luminal diameter
between G4 and G5.
Conclusion: Our results suggested that quercetin may be beneficial in SAH therapy by preventing vasospasm.
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1. Introduction
Cerebral vasospasm (CV) is the most important cause
of morbidity and mortality following subarachnoid
haemorrhage (SAH) [1]. The aim of SAH treatment is
to prevent secondary brain injury by optimising cerebral
blood blow, reducing cerebral metabolic demand, and
avoiding hypoxia [2]. Many pharmacological agents
have been utilised for treatment of CV in both clinical
and experimental studies, including free radical
scavengers, vasodilators such as nitric oxide (NO),
endothelin antagonists, glutamate antagonists and
protein kinase inhibitors [3]. The natural flavonoid,
quercetin (3,3′,4′,5,-pentahydroxyl-flavone), is present
in high concentrations in fruits and vegetables, such as
tea, apples, onions, potatoes, broccoli, and peanuts [4].
As a strong antioxidant and radical scavenger, quercetin

has been shown to have beneficial effects in treatment
of brain oedema and neuronal damage following SAH
in experimental models by protecting against oxidative
stress, and it may achieve efficient therapeutic levels in the
brain as it can pass the blood–brain barrier in contrast to
many other antioxidant agents [3,4].
The present study was designed to investigate the
potential neuroprotective effects of quercetin on CV using
an experimental rat model of subarachnoid haemorrhage,
and to evaluate the cellular changes through biochemical,
pathological, and histomorphometric analyses.
2. Materials and methods
The experimental protocol was approved by the Ethics
Committee of Zonguldak Bülent Ecevit University. The
study was conducted on thirty-eight male albino Wistar
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rats, 4 months old, each weighing between 300 and 350
g, at the Experimental Surgery, Research and Animal
Laboratory of the Faculty of Medicine, Zonguldak Bülent
Ecevit University. All rats were kept under appropriate
environmental conditions and they were divided into five
groups as follows: group 1 (G1, n=8), no experimental
intervention; group 2 (G2, n=8), subarachnoid
physiological saline; group 3 (G3, n=8), SAH; group 4 (G4,
n=7) SAH and low-dose (10 mg/kg) quercetin treatment;
group 5 (G5, n=7), SAH and high-dose (50 mg/kg)
quercetin treatment.
The experimental model was constructed as
described previously [1,3,5]. Rats were anaesthetised by
intraperitoneal injection of ketamine (60 mg/kg) and
xylazine (10 mg/kg). A small suboccipital incision was
made to expose the arch of the atlas, occipital bone, and
atlantooccipital membrane. The cisterna magna was
percutaneously punctured with a 25-gauge butterfly
needle, and 0.30 mL of cerebrospinal fluid was slowly
drawn from animals in all groups except G1. The blood
drawn from the tail artery was injected into the cisterna
magna for approximately 2 min for rats in G3, G4, and
G5. The same amount of physiological saline (0.9% NaCl)
was injected into the cisterna magna of rats in G2. The rats
were then placed in a downward position on an oblique
plane for about 15 min to increase blood flow into the
basal cisternae. Immediately after SAH, quercetin was
administered by gavage to rats in G4 (10 mg/kg) and G5
(50 mg/kg), at intervals of 8 h for 2 days. No drugs were
administered to the rats in G3.
All rats were sacrificed at 48th h under appropriate
conditions. For histological and morphometric studies,
samples from the pons, including the basilar artery (BA),
were postfixed in 10% paraformaldehyde for 3 days and
then embedded in paraffin.
After removal, all tissues were washed twice with cold
saline, placed into glass bottles, labelled and stored at −80
°C until processing. Brain tissues were cut into small pieces
with scissors, and then homogenised in 10 volumes of icecold 150 mM KCI using a glass-Teflon homogeniser (Ultra
Turrax IKA T18 Basic; IKA, Wilmington, NC, USA) for 2
min at 5000 rpm. The homogenate was then centrifuged
at 5000 × g for 15 min, and the supernatant was used
for analysis. High-performance liquid chromatographic
(HPLC) analysis was performed (Shimadzu, Kyoto, Japan)
with an malondialdehyde (MDA) kit (Immundiagnostik
AG, Bensheim, Germany). Measurement of total
antioxidant capacity (TAC) (Randox, Crumlin, UK)
was performed using a spectrophotometer (8UV-1601;
Shimadzu, Kyoto, Japan).
For histological examination, paraffin-embedded
tissue samples from the pons (including the BA) were cut
into sections 5 µm thick using a microtome. The sections

were stained with haematoxylin and eosin (H&E) and
evaluated by light microscopy. Morphometric analyses
were performed by the same pathologist using H&Estained sections obtained from the midportions of the
BA. BA wall thickness and diameter were measured using
a microscope (DMLB-100S; Leica, Solms, Germany)
and Leica QWINPlus v.3.1.0 software. Each BA wall was
measured at four points corresponding to 3, 6, 9 and 12
o’clock. Average values for wall thickness and diameter
were then calculated.
Statistical analyses were performed using SPSS (version
19.0; SPSS Inc., Chicago, IL, USA). Descriptive statistics for
continuous variables are defined as the median, minimum,
and maximum values. The normality of the distribution
was examined by the Shapiro–Wilk test. The Kruskal–
Wallis test was used for comparison of variables between
groups. The Mann–Whitney U with Bonferroni correction
was used in subgroup comparisons between two groups.
In all analyses, P < 0.05 was taken to indicate statistical
significance.
3. Results
The MDA level and TAC calculated at 48 h for G1, G2,
G3, G4, and G5 are shown in Table 1. MDA levels were
significantly higher in G2 and G3 than in G1 (P < 0.05).
The MDA levels in G4 and G5 were significantly decreased
in comparison with G2 (P < 0.05, G4–G2; P < 0.05, G5–
G2). No significant differences in MDA level were found
between G2 and G3 or among G1, G4, and G5. There were
no statistically significant differences in TAC between the
groups (P > 0.05).
Histologically, the structure of the BA in G1 was
consistent with normal rat cerebral arteries, with a
continuous monolayer of endothelium, thin internal
elastic lamina and concentrically oriented layers of smooth
muscle cells surrounding the intima. In G2 and G3,
there was some degree of endothelial swelling with focal
desquamation, increased undulation of the internal elastic
lamina, markedly thickened arterial walls and luminal
narrowing. In G4 and G5, in addition to the endothelial
Table 1. Effects of quercetin on MDA and TAC of rat brain tissue
following experimental subarachnoid haemorrhage.
Group

n

MDA (nmol/g tissue)

TAC (mmol/g tissue)

G1

8

144.32 ± 6.08

0.25 ± 0.05

G2

8

268.16 ± 27.50

0.23 ± 0.02

G3

8

311.59 ± 11.70

0.17 ± 0.02

G4

7

165.02 ± 10.87

0.20 ± 0.02

G5

7

153.10 ± 12.72

0.23 ± 0.02

Data are mean values ± standard deviation.
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swelling with focal desquamation and distortion of some
arteries, the BA walls were thinner and the lumens were
more dilated compared to those in G2. The luminal
diameters were markedly larger in G4 and G5 than in G3.
However, compared with G3, there were no statistically
significant differences in arterial wall thickness in G4 and
G5 (Figures 1–5).
The results of statistical analyses of the morphometric
data for BA wall thickness and luminal diameter are
shown in Table 2. Statistically significant differences were
observed between G1 and G2, G1 and G3, G2 and G4, and
G2 and G5 (P < 0.05).
There were no significant differences in BA thickness
between G3 and G4 or between G3 and G5, but G4 and G5
showed larger luminal diameters than G3 (P < 0.05). There
were no significant differences in BA thickness or luminal
diameter between G4 and G5.
4. Discussion
Subarachnoid haemorrhage is defined as blood between the
arachnoid membrane and pia membrane [6]. Aneurysmal
haemorrhage has the highest incidence in non-traumatic
SAH [6,7]. Blood in the subarachnoid space has an
irritant effect, which leads to vasospasm by activating
antiinflammatory mechanisms [7]. Early brain injury,
seizures, CV, and delayed cerebral ischaemia are important
factors contributing to the poor prognosis of SAH [1]. As
CV is the leading cause of morbidity and mortality, there
have been many experimental animal studies to develop
effective treatments [6,7]. However, there is still only
limited information about the underlying mechanism
of CV. Current treatments for CV following SAH
include triple-H therapy (hypertension, hypervolemia,
haemodilution), prophylactic hyperdynamic postoperative
fluid therapy, and drug therapy [1,6]. As these SAH
treatments have not been definitely proven to prevent CV,
a number of experimental treatment strategies have been
proposed, such as antioxidant drug therapy.
Imbalance in the normal redox state of cells occurs due
to oxidative stress and can cause toxic effects through the
production of free radicals [8]. Although there are many
different mechanisms of free radical production after SAH,
autooxidation of haemoglobin is thought to be the main
source as soon as it is released into the subarachnoid space
[9]. SAH induces the enzymes responsible for reactive
oxygen species (ROS) and inhibits the intracellular
antioxidant systems [1].
Free radicals and peroxides are ROS that trigger
oxidative brain injury after cerebral haemorrhage by
damaging cellular proteins, lipids and DNA [4]. In addition,
glial cells play a role in the development of inflammatory
neurodegeneration, and the major intermediate of glialinduced neurotoxicity is the generation of excessive NO,
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Figure 1. Microscopic view of normal basilar artery in G1 (H&E;
X100).

Figure 2. Microscopic view of increase in basilar artery wall
thickness and luminal narrowing in G2 compared to G1 (H&E;
X100).

which can induce neuronal cell damage by disrupting the
function of the neuronal mitochondrial electron transport
chain [8].
Quercetin treatment was reported to have potential
benefits for conditions involving increased oxidative stress
associated with mitochondrial dysfunction [10]. In the
planning stages of this study, we expected to observe the
antioxidant efficacy of quercetin in an experimental rat
SAH model. In a similar study, Dong et al. investigated
the dose-dependent effect of quercetin against oxidative
stress and brain oedema in an experimental rat model of
subarachnoid haemorrhage [4].
Cho et al. examined the effects of quercetin against
neuronal cell damage and matrix metalloproteinase
(MMP)-9 activity after transient global brain ischaemia
[11]. Pretreatment of primary hippocampal cultures with
quercetin significantly attenuated amyloid b-induced
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Figure 3. Microscopic view of increase in basilar artery wall
thickness and luminal narrowing in G3 compared to G1 (H&E;
X100).

Figure 5. Microscopic view of decrease in basilar artery wall
thickness and increase in luminal narrowing in G5 compared
to G2 (H&E; X100). No statistically significant difference was
observed in basilar artery wall thickness between G5 and G3, but
basilar artery luminal diameters were markedly wider in G5.
Table 2. Effects of quercetin on mean luminal diameter and
wall thickness of the rat basilar artery following experimental
subarachnoid haemorrhage.

Figure 4. Microscopic view of decrease in basilar artery wall
thickness and increase in luminal narrowing in G4 compared
to G2 (H&E; X100). No statistically significant difference was
observed in basilar artery wall thickness between G4 and G3, but
basilar artery luminal diameters were markedly wider in G4.

cytotoxicity, protein oxidation, lipid peroxidation, and
apoptosis [12]. Quercetin plays an important role in
altering the progression of neurodegenerative diseases by its
protective effect against oxidative stress [7].
In the present study, the significant decreases in MDA
levels observed in G4 and G5 suggested that quercetin may
be useful as an alternative antioxidant agent in the treatment
of CV following SAH.
The potent ROS scavenging activity of quercetin is
attributable to its high number of hydroxyl substitutions,
which confer electron-donating ability [13]. In addition
to its free radical scavenging effect, quercetin intensifies
other antioxidant mechanisms against oxidative stress, such
as the chelation of iron and calcium, inhibition of lipid

Group

n

Mean luminal
diameter (μm)

Mean wall
thickness (μm)

G1

8

109.75 ± 1.66

24.06 ± 1.12

G2

8

91.87 ± 2.47

29.56 ± 1.51

G3

8

71.34 ± 1.82

31.90 ± 1.72

G4

7

97.81 ± 4.60

26.96 ± 1.87

G5

7

105.71 ± 3.91

22.53 ± 1.24

Data are mean values ± standard deviation.

peroxidation and inhibition of nitric oxide synthase [14,15].
Oxyhaemoglobin-induced free radical products and
lipid peroxidation are the triggers most strongly implicated
in the pathogenesis of CV [2].
Stimuli for contraction may include alterations in the
balance between vasodilator and vasoconstrictor substances
normally produced in the arterial wall, such as prostacyclin,
NO, endothelins, etc. [2,16].
The increased thickening of arterial walls and narrowing
of the luminal diameter are considered signs of vasospasm
[1]. In the present study, BA wall thickening increased
after SAH and mean luminal diameter values decreased.
Significant improvements in histopathological parameters
were observed following treatment with low and high doses
of hesperidin. In the SAH + low hesperidin and SAH + high
hesperidin groups, the mean values of BA wall thickening
and luminal diameter were similar to those in the control
group.
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Although many studies have demonstrated the
protective effects of quercetin against oxidative stress and
brain oedema, there have been few reports regarding its
effects on CV [4]. Therefore, we investigated the effects of
this agent on vasospasm in neural tissue in an experimental
SAH model. However, this study had some limitations in
that the number of animals was small and the study period
was short. Further studies on SAH with quercetin as an
antioxidant and vasodilator are required.
In conclusion, this is the second study to evaluate
the possible neuroprotective effects of quercetin on CV
in an experimental SAH model. We demonstrated that
administration of quercetin induces dose-dependent
vasodilatation of BA, which could yield neuroprotective
effects. In addition, quercetin appears to be involved in
relieving oxidative damage, possibly by reducing lipid
peroxidation and/or by increasing the total antioxidant

capacity, which may contribute to vascular dilation. Further
studies are needed to confirm these results and to elucidate
the possible biochemical mechanisms underlying the
preventive effect of quercetin on CV.
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